Boston Scientific Launches Sentinol™ Self-Expanding Nitinol Biliary Stent System

(April 8, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced the U.S. launch of its Sentinol™ Self-Expanding Nitinol Biliary Stent System (Sentinol), which has been cleared by the U.S. Food and Drug Administration for the treatment of malignant biliary obstruction.

Malignant biliary obstruction is the blockage of any duct that carries bile from the liver to the gallbladder or from the gallbladder to the small intestine. The major symptoms of malignant biliary obstruction result from failure of bile to reach its proper destination -- a condition often alleviated by the placement of a stent.

The Sentinol system expands Boston Scientific's family of high-performance self-expanding biliary stents, which includes the WALLSTENT® Endoprosthesis and the Symphony® Biliary Stent. With the addition of the Sentinol system, the Company now offers self-expanding stent diameter sizes ranging from 5 mm to 24 mm -- providing new options for matching an appropriate stent to a given set of procedural demands.

"This product launch complements our existing stent portfolio and reflects Boston Scientific's commitment to developing new technology for the peripheral intervention world," said Paul LaViolette, Boston Scientific Senior Vice President and Group President, Cardiovascular. "Adding this new stent to our self-expanding stent matrix gives physicians more options for choosing the right stent."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies, commercialization of new technologies, intellectual property, and other factors described in the Company's filings with the Securities and Exchange Commission.

---

https://news.bostonscientific.com/news-releases?item=58812